Neuphoria Therapeutics Inc. (NEUP) stock
Close on Nov 12, 2026Market cap $77.56KP/E –Yield –
Neuphoria Therapeutics Inc. saw revenue fall 92.5% to $1.17M over fiscal 2026. At the latest close the market valued the company at $77.56K.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $77.56K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.17M
- Net income
- -$13.45M
- EPS, diluted
- -$3.06
- Book value per share
- $4.55
- Diluted shares
- 5M
Trading
- Previous close
- $2.71
- Open
- $2.67
- Day's range
- $2.54 – $2.77
- Volume
- 19,713
- Average volume (20 days)
- 36,892
- Beta (5 years)
- 0.85
- 52-week range
- $2.54 – $5.53
- RSI (14 days)
- 15.6
- Volatility (1 year)
- 51.1%
- Relative volume
- 0.16×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NEUP | S&P 500 | Difference | NEUP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.3% | -2.7% | −19.6 pts | ||
| 3 months | -32.3% | -1.7% | −30.5 pts | ||
| Year to date | -33.5% | +11.9% | −45.4 pts | ||
| 1 year | -47.3% | +12.0% | −59.3 pts | ||
| 3 years | -87.6% | +78.2% | −165.8 pts | -50.2% | +21.2% |
Seven years at a glance
Fiscal years 2020 to 2026, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Neuphoria Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- Results
- News
About Neuphoria Therapeutics
Pharmaceutical Preparations
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on fulfilling public-company obligations, preserving capital, and executing a proposed merger transaction. The company centers its research activities on an alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio. Its primary proprietary asset, BNC210, is maintained in clinical readiness for post-traumatic stress disorder following the discontinuation of its social anxiety disorder program. Neuphoria also manages economic interests in partnered programs, including allosteric modulators partnered with Merck, a KAT6 oncology program licensed to Pfizer, and a CAR-T therapeutic developed by Carina Biotech. Because its assets are clinical-stage therapies, Neuphoria serves no commercial customers.
Company profile, executives and historyNeuphoria Therapeutics stock: common questions
What is Neuphoria Therapeutics's stock price?
NEUP closed at $2.58 on Nov 12, 2026, down 4.80% on the day. Over the past 52 weeks it traded between $2.54 and $5.53.
What is Neuphoria Therapeutics's market cap?
Neuphoria Therapeutics was worth $77.56K at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NEUP's P/E ratio?
Neuphoria Therapeutics lost money over fiscal 2026 (diluted EPS -$3.06), so it has no meaningful P/E ratio.
How much revenue does Neuphoria Therapeutics make?
Neuphoria Therapeutics reported revenue of $1.17M for fiscal 2026, down 92.5% from a year earlier.
Does Neuphoria Therapeutics pay a dividend?
No. Neuphoria Therapeutics has not paid a cash dividend over the last twelve months.
How has NEUP stock performed over the past year?
Including dividends, NEUP returned -47.3% over the past year, against +12.0% for the S&P 500.
Who are Neuphoria Therapeutics's competitors?
Companies most similar to Neuphoria Therapeutics by business, industry and size include IGC, KRSA, DNTH, OVID, ATXI.
See a number that looks wrong?